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The diagnosis between different forms
of raised dermal scarring such ashypertrophic (HTS) and keloid scars
(KS) can be difficult in the absence of a
specific biomarker (Atiyeh, 2007; Leeet al., 2004). Importantly, the differen-
tiation can be critical before initiation
of treatment, as misdiagnosis followed
by inappropriate therapy may result in
worsening of the outcome by
increasing rate of recurrence in keloids
(Viera et al., 2012). Therefore, the aim
here was to identify a molecular diag-
nostic biomarker capable of dis-
tinguishing KS from other forms ofwww.jidonline.org 2319
Figure 1. Representative immunohistochemical micrographs of syndecan-1 (CD138) overexpression in
keloid compared with normal scar and normal skin tissue. There is overexpression of syndecan-1
immunoreactivity within keloid reticular dermis, sparing papillary dermis; scale bar (black) ¼ 1 mm and
scale bar (green) ¼ 50 mm (a), relative to NS and normal skin; scale bar (black) ¼ 500 mm and scale bar
(green) ¼ 100 mm (b). Expression is observed on cells (black arrows) and to some extent in extracellular
matrix (red arrows). Paraffin-embedded tissues for 65 keloid samples, 11 NS, and 11 normal skins were
sectioned at 5 mm. Then, they were dewaxed, dehydrated, and labeled with a syndecan-1 antibody and
detected using chromogen. Slides were scanned using ScanScope (Aperio Technology, Oxford, UK).
Micrographs were captured at 8 magnifications, and inserts were captured at 200 and 400
magnifications. E, epidermis; KS, keloid scar; N, normal skin; NS, normal Scar; PD, papillary dermis; RD,
reticular dermis.
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2320dermal scarring specially HTS and
also dermatofibrosarcoma protuberans
(DFSPs)—an uncommon progressive,
reticular dermal neoplasm with high
recurrence. Often, keloid and/or DFSP
are misdiagnosed (Kimura et al., 2014,
Nguyen et al., 2002, Nicholas and
Stodell, 2014, Suarez et al., 2015). We
have demonstrated immune upregula-
tion and the presence of lymphoidJournal of Investigative Dermatology (2016), Volumaggregates while investigating the pres-
ence of plasma cells in 63 KS tissue
samples (Bagabir et al., 2012) using
immunohistochemistry, and serendipity
that led to the identification of abundant
expression of CD138 in KS. Localized
abundant expression of CD138 within
the keloid lesion had drawn our atten-
tion to further understand the link be-
tween CD138 and keloid.e 136CD138 (syndecan-1) is a cell surface
proteoglycan, which is shed by the
expressing cells into the extracellular
matrix (Szatma´ri et al., 2015).
Syndecan-1 is present in neonatal scars,
while its lack of expression in scar-less
fetal wound healing (Gallo et al.,
1996) suggests a potential functional
role for syndecan-1 in fibrosis in scar
formation. Interestingly, syndecan-1
binds to the collagens and fibronectin
deposited during tissue repair, as a
consequence of which the tissue reverts
to a quiescent state (Szatma´ri et al.,
2015). It modulates cell proliferation,
migration, and tumor progression in
cancer cells (Szatma´ri et al., 2015), and
regulates keratinocyte proliferation and
the proteolytic balance in healing
wounds (Stepp et al., 2015).
To follow up the overexpression of
syndecan-1 in keloid and to probe the
hypothesis that it may be a unique,
previously unreported, biomarker, its
expression in KS was compared with
HTS, DFSP tumor, normal scar (NS), and
normal skin. For all the tissue samples
used in this study, ethical approval was
obtained from NHS Ethical Committee,
Manchester, UK. All cases recruited
gave full informed verbal and written
consent to take part in the study (ethical
reference number 11/NW/0638). The
in situ staining of keloid (n ¼ 65), NS
(n ¼ 11), DFSP (n ¼ 10), HTS (n ¼ 3)
(see Supplementary Material and
Methods online for details), and
normal skins (n ¼ 11) showed a clear
overexpression of syndecan-1 in keloid
when compared to HTS, DFSP, NS,
and normal skin. Keloid cross-sections
revealed an intensive immune reac-
tivity of syndecan-1 within keloid
reticular dermis (Figure 1a and
Supplementary Figure S1 online),
whereas perilesional skin lacked its
expression. Surprisingly, in situ
syndecan-1 expression was mild to
absent in HTS and NS, respectively,
and completely absent in healthy skin
and in DFSP tumors when compared
with keloid (Figures 1b and 2a and
Supplementary Figures S1eS5 online).
However, the expression pattern of
syndecan-1 was variable in between the
keloid samples from different patients
and/or different anatomical sites
(Supplementary Figure S1 and Table S1
online). Minimal to no expression of
syndecan-1 was detected in HTS
ab c
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Figure 2. Significant overexpression of syndecan-1 (CD138) at transcriptional and translational level in keloid tumor compared with normal scar and normal
skin. (a) Bar graphs represent the immunomorphometric quantitative analysis of CD138 expression in keloid (KS, n ¼ 9), hypertrophic scars (HTS, n ¼ 3), and in
DFSP (n ¼ 10) tumor tissue samples. A significant increase in syndecan-1 protein expression (*P ¼ 0.001) was detected in keloid as compared with HTS and
DFSP tumor tissue. (b) Overexpression of mRNA in keloid intralesional tissue compared with hypertrophic scar (HTS), normal scar (NS), and normal skin (N)
dermal tissue. Fold change of syndecan-1 mRNA in the KS-defined lesional site relative to HTS, NS, and normal skin. Primers for syndecan-1 were designed
(Supplementary Table S5 online). mRNAwas extracted from full-thickness tissue derived from defined KS site intralesion (n ¼ 9), HTS (n ¼ 4), NS dermis (n ¼ 8),
and normal skin dermis (n ¼ 7). Two micrograms of mRNA was reverse transcribed and the quantitative real-time RT-PCR reaction was carried out. The cycle
threshold (Ct) values were normalized to the geometric mean of two housekeeping genes (SDHA: succinate dehydrogenase complex subunit A and RPL32: 60S
ribosomal protein L32) and analyzed by fold change (2DDCT) relative to NS and normal skin. Error bars represent mean  SEM. (c) Ex vivo quantitative
measurement of syndecan-1 in keloid, NS, and normal skin dermal lysates. Syndecan-1 protein was extracted from keloid (n ¼ 8) intralesional site (core of the
keloid tissue) and dermis of NS (n ¼ 6) and normal skin (n ¼ 6), using modified radioimmunoprecipitation assay buffer. ELISA was performed in triplicate as
described in Supplementary Material and Methods. Results are presented as mean  SEM. (d) Syndecan-1 expression profile in keloid (core region of keloid),
HTS, NS, and normal skin primary fibroblasts isolated from the dermis. Serum-starved keloid fibroblasts were seeded in 96-well plates (1.0  104 cells/well) and
grown up to 24 hours. The cells were then fixed with 4% formaldehyde/phosphate-buffered saline. After blocking, syndecan-1 was detected by incubation with
anti-CD138, followed by incubation with an IRDye 800-labeled secondary antibody. The representative output infrared image of a 96-well plate shows the
syndecan-1 expression pattern across different fibroblast cell lines. (e) Bar graphs represent the quantification of mean syndecan-1 protein expression in
KS, HTS, NS, and normal skin primary fibroblast cell lines. Results are presented as mean  SEM of triplicates (n ¼ 6). HTS, hypertrophic scars; KS, keloid scar;
N, normal skin; NS, normal scar; SEM, standard error of the mean.
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SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online
version of the paper at www.jidonline.org, and at
http://dx.doi.org/10.1016/j.jid.2016.06.623.
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2322and NS dermis, but consistent higher
expression was seen in keratinocytes
and endothelial cells in all the
tissue samples including DFSP
(Supplementary Figures S2eS5). Inter-
estingly, syndecan-1 immunoreactivity
was localized within the keloid tumor
mass, keloid stroma, and epidermis,
sparing papillary dermis. Its expression
was both cellular and in the extracel-
lular matrix. However, the expression of
syndecan-1 was absent in the dermis in
normal skin adjacent to keloid
tissue (extralesional) (Figure 1a and
Supplementary Figure S1).
To further corroborate the above
findings and to compare CD138
expression between KS and HTS, we
assessed its mRNA and protein expres-
sion in KS (n ¼ 13), HTS (n ¼ 10), NS
tissue (n ¼ 9), and healthy skin
(n ¼ 8) by quantitative RT-PCR, ELISA,
and in-cell western blotting (see
Supplementary Material and Methods
for details, and Supplementary
Tables S1eS4 online for patient de-
mographic data). The results corre-
sponded with a significant increase
in syndecan-1 gene expression (P ¼
0.001) in keloid relative to NS, normal
skin, as well as HTS (Figure 2b).
Despite the increased expression of
CD138 at mRNA level in HTS
compared with controls, there was no
statistically significant difference (P >
0.05). Therefore, quantitative protein
analysis was also conducted in keloid,
HTS, NS, and normal skin. Syndecan-1
protein level was significantly overex-
pressed (P ¼ 0.001) in keloid dermis
using anti-human syndecan-1 ELISA
and in cultured keloid fibroblasts using
the in-cell western blotting technique
(see Supplementary Material and
Methods for details), relative to NS
and normal skin (Figure 2cee).
Although there was a significant in-
crease in the expression of syndecan-1
in HTS and NS tissue compared with
normal skin (P < 0.05), this could also
reflect endogenous syndecan-1 from
either immune cells and/or epithelial
cells from adnexal structures/sweat
glands in HTS and NS dermis, which
was also detected in the tissue staining
(Supplementary Figures S2eS4).
Syndecan-1 plays an important role
as a cell adhesion and growth factor-
binding molecule not only during
embryogenesis but also during tissueJournal of Investigative Dermatology (2016), Volumregeneration in mature tissues. Over-
expression of syndecan-1 in basal ker-
atinocytes promotes proliferation
during epidermal development, but re-
stricts proliferation during wound
healing (Stepp et al., 2015). Currently,
the mechanism behind high expression
of syndecan-1 in epidermis across all
the tissue samples used in this study
remains unclear. Based on increasing
insight into the role of syndecan-1 in
the pathobiology of fibrotic diseases
and cancer, to our knowledge previ-
ously unreported, our findings
encourage one to follow up, next,
whether syndecan-1 is functionally
involved in the progression of fibro-
genesis and the maintenance of
chronic, fibrogenic inflammation in KS
(Bagabir et al., 2012). It has previously
been shown that microRNA-143 is
downregulated in melanoma and
negatively regulates overexpressed
syndecan-1 (Li et al., 2014). Interest-
ingly, a comparative study of microRNA
profiling in fibroblast also showed that
microRNA-143 is downregulated in
keloid (Li et al., 2013). This may be
investigated most instructively in the KS
organ culture, using previously pub-
lished in situ gene knockdown tech-
niques (Syed et al., 2013). The
distinction between DFSP tumor and
scar tissue surrounding the tumor in the
DFSP sample is quite interesting in
terms of syndecan-1 expression and
needs further elucidation. Histologi-
cally, scar tissue consists of fascicles of
fibroblasts/myofibroblasts that have
relatively plump nuclei as opposed to
the slender nuclei of DFSP. Moreover,
the fascicles in scar tissue are longer
and have horizontal orientation as
opposed to DFSPs that in typical cases
have short fascicles arranged in a
prominent storiform pattern. CD34 also
helps to distinguish scar tissue from
DFSPs. The former is generally nega-
tive, whereas DFSPs show strong and
diffuse staining. Furthermore, the
lesional cells that constitute DFSPs are
fibrohistiocytic cells or cells related to
dermal dendritic cells and not pure fi-
broblasts, whereas in scar tissue sur-
rounding to DFSP tumor may have a
keloid-like environment or may have
mainly myofibroblasts, hence the dif-
ference in expression of CD138, which
need to be further investigated in future.
In summary, one can use a combinatione 136of morphological analysis and CD34
immunostaining to distinguish scar tis-
sue from DFSP (Prieto et al., 1994). It
can however be difficult in some cases;
therefore, CD138 may add to the
ancillary studies used in solving this
dilemma.
In conclusion, we have shown, pre-
viously unreported, that syndecan-1 is
significantly overexpressed in keloid
compared with HTS and NS, and
completely absent in DFSP. Beyond its
potential value as a biomarker, to our
knowledge previously unreported, to
distinguish between keloid and HTS,
syndecan-1 can also be used as a vital
diagnostic marker to distinguish misdi-
agnosis between keloid and DFSP, as it
has been clearly shown in the tumor
tissue samples in this study and in the
previous studies, corroborating our
findings, that DFSPs do not express
syndecan-1 in dermis (O’Connell et al.,
2004; Orosz and Kopper, 2000).
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